Cargando…

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy

PURPOSE: Cancer vaccines are a promising therapeutic approach in cancer immunotherapy and can inhibit tumor growth and prevent tumor recurrence and metastasis by activating a sustained antitumor immunoprotective effect. However, the therapeutic effect of cancer vaccines is severely weakened by the l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Peiqi, Xu, Yuanlin, Ji, Wei, Li, Lanfang, Qiu, Lihua, Zhou, Shiyong, Qian, Zhengzi, Zhang, Huilai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752078/ https://www.ncbi.nlm.nih.gov/pubmed/35027827 http://dx.doi.org/10.2147/IJN.S346044

Ejemplares similares

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
por: Zhao, Peiqi, et al.
Publicado: (2021)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma
por: Wu, Zizheng, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
por: Qiu, Lihua, et al.
Publicado: (2022)

Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
por: Chen, Jie, et al.
Publicado: (2021)

Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review
por: Fang, Xingliang, et al.
Publicado: (2022)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

In Situ Cocktail Nanovaccine for Cancer Immunotherapy
por: Liu, Mohan, et al.
Publicado: (2023)

Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
por: Zhang, Huilai, et al.
Publicado: (2022)

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
por: Zhang, Tingting, et al.
Publicado: (2022)

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
por: Gao, Fenghua, et al.
Publicado: (2022)

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

A Magnetic Nanovaccine Enhances Cancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2019)

Artificially cloaked viral nanovaccine for cancer immunotherapy
por: Fusciello, Manlio, et al.
Publicado: (2019)

CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Envelope virus-mimetic nanovaccines by hybridizing bioengineered cell membranes with bacterial vesicles
por: Zhang, Mengmeng, et al.
Publicado: (2022)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin, Xiaoning, et al.
Publicado: (2021)

Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy
por: Zhan, Jing, et al.
Publicado: (2023)

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
por: Ni, Qianqian, et al.
Publicado: (2020)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
por: Jing, Weiqing, et al.
Publicado: (2015)

Membrane-based cancer nanovaccines: the time is now
por: Zhao, G, et al.
Publicado: (2023)

Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
por: Dong, Ying, et al.
Publicado: (2020)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pepnnqlh1aclh73tvb8qgb1aoe